HARVARD BIOSCIENCE INC (HBIO) Stock News
NASDAQ:HBIO - Nasdaq - US4169061052 - Common Stock - Currency: USD
HBIO Latest News, Press Relases and Analysis
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive...
Harvard Bioscience Announces Third Quarter 2024 Financial Results
HOLLISTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the...
Harvard Bioscience Announces Third Quarter 2024 Financial Results
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended...
HBIO Stock Earnings: Harvard Bioscience Misses Revenue for Q2 2024
HBIO stock results show that Harvard Bioscience missed on revenue for the second quarter of 2024.
HBIO Stock Earnings: Harvard Bioscience Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Harvard Bioscience (NASDAQ:HBIO) just reported results for the fourth quarter o...
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024
New products complement an already extensive range of products enabling fundamental advancements in neuroscience research
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development...
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive...
Harvard Bioscience Announces Second Quarter 2024 Financial Results
HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the...
Harvard Bioscience Announces Second Quarter 2024 Financial Results
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended...
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive...
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive...
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive...
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
HBIO Stock Earnings: Harvard Bioscience Meets EPS, Misses Revenue for Q1 2024
HBIO stock results show that Harvard Bioscience met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Harvard Bioscience Announces First Quarter 2024 Financial Results
Strong gross margin performance and focus on efficiency to support ongoing investments in growth...
Harvard Bioscience Announces First Quarter 2024 Financial Results
Strong gross margin performance and focus on efficiency to support ongoing investments in growth
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended...
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its...
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive...
HBIO Stock Earnings: Harvard Bioscience Misses EPS, Misses Revenue for Q4 2023
HBIO stock results show that Harvard Bioscience missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating income of...
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics...
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics